Ryan Cawood

Chief Scientific Officer • WuXi Advanced Therapies

Ryan founded Oxford Genetics (trading as OXGENE) in 2011, after earning a degree in genetics and a PhD in gene therapy from Oxford University. The idea behind the company was to simplify and standardise the process of DNA engineering using a proprietary DNA plasmid platform called SnapFast™. Ryan used his background in virology to guide and grow the business through a series of strategic changes that deployed the SnapFast™ technology for cell and gene therapy discovery and manufacturing applications. He has over 20 peer reviewed papers and is the inventor on more than 100 international patent applications. In 2021, Ryan led the sale of the OXGENE to WuXi Advanced Therapies. He is currently the Chief Scientific Officer for WuXi Advanced Therapies and OXGENE.

Also Speaking

Lizette Caballero

Regional CAR T Site Liaision • Janssen

Eugene Brandon

Head, Cell & Gene Therapy Translation • IQVIA

Kevin Ramdas

Director, Medical Affairs • Longeveron

Event Info


Fun Run